Guangzhou Kingmed Diagnostics Group Co., Ltd.

SHSE:603882 Stock Report

Market Cap: CN¥11.0b

Guangzhou Kingmed Diagnostics Group Future Growth

Future criteria checks 3/6

Guangzhou Kingmed Diagnostics Group is forecast to grow earnings and revenue by 65.2% and 10.2% per annum respectively. EPS is expected to grow by 65.2% per annum. Return on equity is forecast to be 6.6% in 3 years.

Key information

65.2%

Earnings growth rate

65.16%

EPS growth rate

Healthcare earnings growth18.2%
Revenue growth rate10.2%
Future return on equity6.63%
Analyst coverage

Good

Last updated06 May 2026

Recent future growth updates

Recent updates

Analysis Article • Mar 17

Is Guangzhou Kingmed Diagnostics Group (SHSE:603882) A Risky Investment?

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Analysis Article • Feb 10

Guangzhou Kingmed Diagnostics Group Co., Ltd.'s (SHSE:603882) Business Is Yet to Catch Up With Its Share Price

It's not a stretch to say that Guangzhou Kingmed Diagnostics Group Co., Ltd.'s ( SHSE:603882 ) price-to-sales (or...
Analysis Article • Dec 13

Guangzhou Kingmed Diagnostics Group (SHSE:603882) Has A Pretty Healthy Balance Sheet

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Analysis Article • Nov 06

Guangzhou Kingmed Diagnostics Group's (SHSE:603882) Weak Earnings May Only Reveal A Part Of The Whole Picture

The market wasn't impressed with the soft earnings from Guangzhou Kingmed Diagnostics Group Co., Ltd. ( SHSE:603882...
Analysis Article • Sep 27

Earnings Tell The Story For Guangzhou Kingmed Diagnostics Group Co., Ltd. (SHSE:603882)

With a price-to-earnings (or "P/E") ratio of 32.4x Guangzhou Kingmed Diagnostics Group Co., Ltd. ( SHSE:603882 ) may be...
Analysis Article • Sep 03

Guangzhou Kingmed Diagnostics Group Co., Ltd. Just Missed Revenue By 9.5%: Here's What Analysts Think Will Happen Next

The analysts might have been a bit too bullish on Guangzhou Kingmed Diagnostics Group Co., Ltd. ( SHSE:603882 ), given...
Analysis Article • Aug 25

Is Guangzhou Kingmed Diagnostics Group (SHSE:603882) Using Too Much Debt?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Analysis Article • Jun 04

A Look At The Fair Value Of Guangzhou Kingmed Diagnostics Group Co., Ltd. (SHSE:603882)

Key Insights Guangzhou Kingmed Diagnostics Group's estimated fair value is CN¥27.40 based on Dividend Discount Model...
Analysis Article • May 02

Guangzhou Kingmed Diagnostics Group's (SHSE:603882) Shareholders Have More To Worry About Than Only Soft Earnings

Investors were disappointed by Guangzhou Kingmed Diagnostics Group Co., Ltd.'s ( SHSE:603882 ) latest earnings release...
Analysis Article • Apr 17

Investors Don't See Light At End Of Guangzhou Kingmed Diagnostics Group Co., Ltd.'s (SHSE:603882) Tunnel And Push Stock Down 26%

Guangzhou Kingmed Diagnostics Group Co., Ltd. ( SHSE:603882 ) shares have had a horrible month, losing 26% after a...
Analysis Article • Feb 28

Investor Optimism Abounds Guangzhou Kingmed Diagnostics Group Co., Ltd. (SHSE:603882) But Growth Is Lacking

With a median price-to-earnings (or "P/E") ratio of close to 31x in China, you could be forgiven for feeling...

Earnings and Revenue Growth Forecasts

SHSE:603882 - Analysts future estimates and past financials data (CNY Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20287,766589N/A9234
12/31/20277,039514N/A9687
12/31/20266,1893391,1159176
3/31/20265,915-1037661,191N/A
12/31/20256,030-1737791,202N/A
9/30/20256,109-5558751,266N/A
6/30/20256,306-5568101,223N/A
3/31/20256,815-3906431,099N/A
12/31/20247,190-381460906N/A
9/30/20247,8491615321,035N/A
6/30/20248,112448279911N/A
3/31/20248,263475195873N/A
12/31/20238,5406435161,231N/A
9/30/20239,5788823421,126N/A
6/30/202311,4721,3977291,448N/A
3/31/202313,3422,0541,3252,077N/A
12/31/202215,4762,7551,1071,948N/A
9/30/202215,5342,9961,4632,352N/A
6/30/202214,8002,8031,3492,325N/A
3/31/202213,5162,5321,0182,018N/A
12/31/202111,9432,2201,1362,088N/A
9/30/202111,0342,1277871,646N/A
6/30/202110,2252,0131,1761,900N/A
3/31/20219,7522,0001,1761,802N/A
12/31/20208,2441,5109721,523N/A
9/30/20207,1761,1388071,240N/A
6/30/20206,201787383745N/A
3/31/20205,276408236555N/A
12/31/20195,269402N/A661N/A
9/30/20195,128388N/A635N/A
6/30/20194,954309N/A571N/A
3/31/20194,771266N/A558N/A
12/31/20184,525233N/A530N/A
9/30/20184,309205N/A384N/A
6/30/20184,107200N/A340N/A
3/31/20183,909191N/A289N/A
12/31/20173,792189N/A284N/A
9/30/20173,689198N/A292N/A
12/31/20163,222170N/A292N/A
9/30/20163,010153N/A253N/A
12/31/20152,389140N/A220N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 603882 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.4%).

Earnings vs Market: 603882 is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: 603882 is expected to become profitable in the next 3 years.

Revenue vs Market: 603882's revenue (10.2% per year) is forecast to grow slower than the CN market (16.8% per year).

High Growth Revenue: 603882's revenue (10.2% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 603882's Return on Equity is forecast to be low in 3 years time (6.6%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/06 16:51
End of Day Share Price 2026/07/06 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Guangzhou Kingmed Diagnostics Group Co., Ltd. is covered by 15 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Pei ChengChina Galaxy Securities Co., Ltd.
Jin ZhangChina International Capital Corporation Limited
Sherry YeChina Stock Investment Research Co. Ltd. (GZ500..com)